Edition:
United States

Profile: InVivo Therapeutics Holdings Corp (NVIV.PH)

NVIV.PH on Philadelphia Stock Exchange

0.63USD
22 Jul 2019
Change (% chg)

-- (--)
Prev Close
$0.63
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
339
52-wk High
$2.60
52-wk Low
$0.63

InVivo Therapeutics Holdings Corp., formerly Design Source, Inc., incorporated on April 2, 2003, is a research and clinical-stage biomaterials and biotechnology company. The Company is engaged in developing and commercializing biopolymer-scaffolding devices for the treatment of spinal cord injuries (SCI). The Company's approach to treating acute SCIs is based on its investigational Neuro Spinal Scaffold implant, an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord contusion and is intended to treat acute spinal cord injury. It is also evaluating other technologies and therapeutics that may be complementary to its development of the Neuro-Spinal Scaffold implant. The Company has a clinical development program for acute SCI and a preclinical development program for chronic SCI.

Neuro-Spinal Scaffold implant for acute SCI

The Company's product under development is Neuro-Spinal Scaffold. The Neuro-Spinal Scaffold implant is intended to provide support to the surrounding tissue after injury, minimizing expansion areas of necrosis and supporting endogenous healing/repair processes following injury. The Neuro-Spinal Scaffold is surgically implanted at the epicenter of the wound and acts as a physical substrate for nerve sprouting. The Neuro-Spinal Scaffold consists of biocompatible and bioresorbable polymers, which include poly lactic-co-glycolic acid (PLGA), a polymer that is used in resorbable sutures and provides the biocompatible support for Neuro-Spinal Scaffold implant, and Poly-L-Lysine (PLL), a positively charged polymer commonly used to coat surfaces in order to promote cellular attachment. The Company has completed a feasibility human pilot study of Neuro-Spinal Scaffold.

Bioengineered Neural Trails injection program for chronic SCI

The Company is also focused on Bioengineered Neural Trails injection program for the treatment of chronic spinal cord injury. Bioengineered Neural Trails are injectable combinations of biomaterials and neural stem cells (NSCs) delivered using minimally-invasive surgical instrumentation and techniques to create trails across the chronic injury site.

Company Address

InVivo Therapeutics Holdings Corp

1 Kendall Sq
CAMBRIDGE   MA   02139-1562
P: +1617.8635524

Company Web Links